- Home
- DAVA vs STXS Comparison
DAVA vs STXS Comparison
Compare DAVA & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | STXS |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 139.3M |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | DAVA | STXS |
|---|---|---|
| Price | $2.96 | $1.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $13.50 | $4.00 |
| AVG Volume (30 Days) | 198.9K | ★ 482.0K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | $4.07 | $30.47 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.55 | $1.24 |
| 52 Week High | $9.97 | $3.59 |
Technical Indicators
Market Signals| Indicator | DAVA | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 39.90 |
| Support Level | $2.67 | $1.30 |
| Resistance Level | $3.03 | $1.51 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 31.75 | 18.37 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.